BackOrchard Therapeutics plc Overview

Orchard Therapeutics plc Other Current Assets

Track Orchard Therapeutics plc's other current assets ($7.5M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$7.45M
33.83% YoYΔ $-3.81M vs prior year quarter

Peer average / median

Loading

Orchard Therapeutics plc Other Current Assets History

Loading

Orchard Therapeutics plc vs. peers: Other Current Assets Comparison

Loading

Orchard Therapeutics plc Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Orchard Therapeutics plc (ORTX) FAQ

As of the most recent data (September 2023), ORTX shows a other current assets of $7.5M. That compares with $11M in the prior-year period — down 33.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ORTX's other current assets is now $7.5M (was $11M) — a 33.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Orchard Therapeutics plc is outperforming or lagging.

Tracking ORTX's other current assets over time shows whether Orchard Therapeutics plc is scaling, shrinking, or reshaping that part of the business. The current reading is $7.5M That compares with $11M in the prior-year period — down 33.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current assets page, Stockcircle has Orchard Therapeutics plc's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current assets (currently $7.5M) with ownership activity and broader fundamentals.

Orchard Therapeutics plc's other current assets is $7.5M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.